1	0	6	9	2	8	5

To: 5.1.2e)[5.1.2e @minvws.nl]; 5.1.2e)[5.1.2e @minvws.nl] From: 5.1.2e)	52
Sent: Fri 1/29/2021 6:17:39 PM Subject: FW: EU COVID-19 Vaccine AstraZeneca recommended for use in the EU Received: Fri 1/29/2021 6:17:40 PM mage001.jpg AZD1222 EMA recomendation RNS.pdf	
5.1.2e 5.1.2e Ministerie van Volksgezondheid, Welzijn en Sport Parnassusplein 5 Postbus 20350 2500 EJ Den Haag 0 06 5.1.2e (secretariaat: * 06 5.1.2e Image: State of the state	
Van: 5.1.2e 0 < 5.1.2e	
fyi	
Van: 5.1.2e) < 5.1.2e	
Dames,	
Graag bijgaande brief innemen en uitzetten bij de programma directie Covid-19	

Groet,

Verzonden met BlackBerry Work(www.blackberry.com)

Van: " 5.1.2e " < 5.1.2e @astrazeneca.com>
 Verzonden: 29 jan. 2021 18:13

 Naar: Minister van VWS <</th>
 5.1.2e
 @minvws.nl>

 Cc: "
 5.1.2e
 @astrazeneca.com>

Onderwerp: EU COVID-19 Vaccine AstraZeneca recommended for use in the EU

Dear Minister De Jonge, Dear Minister Van Ark,

Herewith we would like share with you the news that EMA has just recommended granting a conditional marketing authorization (CMA) for our COVID-19 AstraZeneca vaccine.


We anticipate the European Commission will shortly approve a CMA for active immunisation to begin across EU Member States and have shared last week the latest delivery schedules pending approval.

AstraZeneca Covid-19 vaccine:

- Authorisation is for active immunisation of adults 18 years or older
- The authorisation recommends two doses administered with an interval of 4 to 12 weeks .

We hope with this approval we can contribute to exiting this Covid crisis. We would be more than happy to brief you and your teams in more detail if helpful.

Please do not hesitate to reach out should you have any questions.



AstraZeneca UK Limited is a company incorporated in England and Wales with registered number:03674842 and its registered office at 1 Francis Crick Avenue,

Cambridge Biomedical Campus, Cambridge, CB2 0AA. This e-mail and its attachments are intended for the above named recipient only and may contain confidential and privileged information. If they have come to you in error, you must not copy or show them to anyone; instead, please reply to this e-mail, highlighting the error to the sender and then immediately delete the message. For information about how AstraZeneca UK Limited and its affiliates may process information, personal data and monitor communications, please see our privacy notice at www.astrazeneca.com